Resperate®-InterCure Ltda
DeviceThe device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
NCT Number: NCT02608827
Hypertension is serious health problem in Brazil and affects almost 30%of adult population. It is known that there are pharmacologic and nonpharmacologic strategies for treating hypertension. Aerobic exercise and slow breathing are nonpharmacologic methods that reduce blood pressure in an isolated form, but its combinations has never been studied. The aim of this study is to evaluate the association of both strategies and also the mechanisms involved in blood pressure reduction using slow breathing, in stages 1 and 2 hypertensives.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
The combination of drugs and no medication for hypertension treatment has been widely recommended, with emphasis on aerobic exercises (EXE), relaxation exercises, and the use of equipment designed to decrease the respiratory rate called Resperate®. This intervention has demonstrated a hypotensive effect in pressure measurements in clinical blood pressure and ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM). It is unknown; however, if slow breathing (GRL) associated with other intervention, such as EXE, for example, may potentiate the blood pressure (BP) reduction. The aim of this study will be evaluate the acute responses of muscle sympathetic nerve activity (MSNA) and BP, in association of the slow breathing versus control (listening to calm music) and the 24 hour blood pressure response after the association of EXE and GRL. Twenty hypertensives will be evaluated between 18 to 60 years old, mens and woman, sedentary, non-obese, without target organs damage and associated comorbidities, after 4 weeks of placebo use (washout period). Participants will be randomly divided into 2 groups (GRL and GC) and both perform EXE on a cycle ergometer. Volunteers will make a ABPM before and after the experimental session. In this session will be recorded for 10 minutes, prior to the physical exercise, the systolic blood pressure (SBP), diastolic blood pressure (DBP), respiratory rate (RR) and heart rate (HR), after that, It will be held microneurography to register also the MSNA for 10 minutes, then they will perform either GRL or listened to music for 15 minutes. Variables will be measures for more 10 minutes. After finishing the session, volunteers will put the ABPM and will go away.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
The patients in this arm will hear slow music - Music group (GC).
Time frame: A session (1 day), after the placebo period of 30 days.
The reduction in blood pressure in mmHg immediately after after a single session of the association of aerobic exercise and guided slow breathing and during 24 hours blood pressure monitoring (ABPM).
Time frame: A session (1 day), after the placebo period of 30 days.
The sympathetic nerve activity will be measured by microneurography technique (burst/min), after a single session of bike aerobic exercise and slow breathing with a guided device.
University of Sao Paulo General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05158569
Cardiovascular Diseases, Hypertension
Swāt, KPK, Pakistan
View Trial DetailsNCT02439775
Cardiovascular Diseases, Hypertension
Huntsville, Alabama, United States
View Trial DetailsNCT07735468
Behavior, Cardiovascular Diseases
Osuna, Sevilla, Spain
View Trial DetailsNCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial Details